A look back at a transformative year for pharma
The UK's exit from the EU will bring disruption to the pharma industry in 2019 – and any upside will remain in the future
How CSOs can look to the future to forge successful relationships with pharma
Successful treatment development relationships rely on the ability of contract research organisations to bring their skills to the table – and pharma’s willingness to let that happen
The implications of adalimumab’s European patent expiry
The National Institute for Health and Care Excellence (NICE) has recommended Pierre Fabre’s Bravtovi and Mektovi combination as an option for some people with melanoma.
18th January 2019
Johnson & Johnson’s Janssen has announced a research study using the Apple watch to help improve atrial fibrillation (AFib) outcomes, including stroke prevention, intending to to collaborate with Apple to assess the impact of the wearable technology on earlier detection of AFib, improved diagnosis and patient outcomes.
18th January 2019
United Neuroscience has announced a positive top-line results from the Phase IIa clinical study of UB-311 vaccine in patients with Alzheimer's disease.
18th January 2019
The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Venclyxto to benefit thousands of adults with chronic lymphocytic leukaemia.
18th January 2019
Novartis and the University of Oxford’s Big Data Institute have announced that they are to establish a five-year research alliance using artificial intelligence to understand complex diseases and improve drug development.
18th January 2019
CRISPR has the potential to transform a variety of scientific areas, but this genome editing technique is also shrouded in controversy, particularly regarding its potential use to create genetically engineered humans.
The health of the life sciences sector in 2019 will continue to be a major focus as the UK navigates all the issues surrounding Brexit.
Saddam Huq, global QA senior manager, Distribution & Cold Chain, at GlaxoSmithKline, speaks to PharmaTimes about temperature excursions and managing the associated risks on a global scale.
The traditional pharma industry is eyeing the rise of Digital Therapeutics as patient outcomes fast become the only metric to sweat over. Their combined effect is setting the scene for a radical transformation of the industry. Its survival as a dominant force in shaping healthcare will depend on how it responds.
The UK's exit from the EU will bring disruption to the pharma industry in 2019 – and any upside will remain in the future
This year pharma began to turn its eye towards the power of the microbiome
The NHS has been taking an increasingly joined-up approach to care during 2018, significantly altering how it works with pharma
The true impact of biosimilars is starting to be felt across the industry
...But this year its impact, and the potential for change, was felt across the pharma industry
The biggest cases of the past year
James Huang & Stephen Huang on the groundbreaking technologies that could change precision medicine in the near future
The value and volume of deals in H1 were higher than in the full year 2017, but a slow second half puts us a long way off 2015’s records
Ashfield wants to change the perception of CSOs and their role within pharma
The one consistent theme in today’s market place is complexity
Many of us recognise that we need others’ knowledge to address the opportunities and challenges we face, yet we still lack the time or motivation to collaborate
The connectivity made possible by the Internet of Things (IoT) has provided new opportunities for businesses to put their buildings to work and reap the rewards
Across all industries, people are changing the ways they engage with products, services, and brands. View more...
Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW
